UCB (EBR:UCB) UCB Media Room: Capture the Fracture Partnership

Transparency directive : regulatory news

16/06/2020 07:01

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513= 9PTmAm2ORJ-2Fb7C-2B6empSJP3S5WNEmfu8d-2FxLPeXZI0N3l4-2FkTXeF1QEkdEwR7Sl1Uns= -2B4XQywhGhd1QxgZTMQlXi30kaZZmUgeXR0jEKDGo_xDPID0vOuylFAU8fv4e60wei4JxqEGBd= VWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9= c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLu= a4VsoarxeD0Q5c5EzzTZzSxRY39vwp0gv33z2hCGCUijGL3OmcXkO167L0mE0WPBfMOvYAoA8pW= TPNhIQtCXUawyvlHHeyP5Pk7rr7vPWRIIbYuQCVbkF8D5DQtN8Dk8hbmJ7AJT279nLoJYEWe9Mo= 8xd3yT0ahWJqgMIAxn9vK4yO1ZtrseUrFHEkk-3D ** New Capture the Fracture Partnership aims for 25 Percent Reduction in th= e Incidence of Hip and Vertebral Fractures due to Osteoporosis by 2025 ------------------------------------------------------------ =C2=B7 International Osteoporosis Foundation Announces First of Its Kind Pa= rtnership with University of Oxford, UCB and Amgen to combat global public = health burden of osteoporosis^1 =C2=B7 Hip and vertebral fractures are costly for society and can be life-a= ltering for patients^2,3 BRUSSELS, Belgium (16th June, 2020): UCB (Euronext Brussels: UCB) and Amgen= (NASDAQ: AMGN) today announced a collaboration with the International Oste= oporosis Foundation (IOF) to support its Capture the Fracture^=C2=AE progra= m to reduce hip and vertebral fractures by 25% by 2025. Currently, it is es= timated that more than 200 million people worldwide suffer from osteoporosi= s^4, resulting in an osteoporosis-related fracture every three seconds.^5 Osteoporosis is a serious chronic condition that weakens bone over time, ma= king them thinner and more likely to break,^5 but there are steps patients = and healthcare providers can take to reduce fracture risk.^1 Capture the Fr= acture, an IOF initiative, now supported by Amgen and UCB in collaboration = with the University of Oxford, is a global program that helps to proactivel= y implement post-fracture care (PFC) coordination programs in hospitals and= healthcare systems to help patients prevent subsequent fractures due to os= teoporosis. Even after an osteoporosis-related fracture approximately 80% o= f individuals at high risk are still not identified or treated.^6 =E2=80=9COsteoporosis remains a global concern, resulting in 8.9 million fr= actures in a single year^3 and a previous fracture increases the risk of an= other osteoporosis-related fracture by 86 percent.^7 Early intervention thr= ough improved post-fracture identification, diagnosis and treatment in appr= opriate patients can help improve outcomes while also lessening the cost bu= rden on healthcare systems^5,=E2=80=9D said Darryl Sleep, M.D., senior vice= president of Global Medical and chief medical officer at Amgen. =E2=80=9CS= upporting Capture the Fracture represents our proactive approach to care de= signed to predict and help prevent potentially life-altering fractures befo= re they happen.=E2=80=9D =E2=80=9CWe are currently witnessing a significant disease burden. As the w= orldwide aging population steadily increases, it has never been more import= ant to address the impact that osteoporosis and associated fractures can ha= ve on individuals,=E2=80=9D said Professor Cyrus Cooper, president of the I= nternational Osteoporosis Foundation and Professor of Musculoskeletal Scien= ce at the University of Oxford. =E2=80=9CWe know post-fracture co-ordinated care implementation is the most= effective^8 and efficient intervention to close the secondary fracture pre= vention gap, so I=E2=80=99m delighted that Amgen, UCB and the University of= Oxford will support our Capture the Fracture program as we embark on a mis= sion to improve outcomes for patients,=E2=80=9D said IOF chief executive of= ficer, Dr. Philippe Halbout. Osteoporosis is treated by multiple specialties, underscoring the need for = coordinated care to support patients with the disease. At the core of the C= apture the Fracture model is a care coordinator who can help patients with = an osteoporosis-related fracture be identified, screened, diagnosed and app= ropriately treated to reduce their future fracture risk. Post-fracture care= coordination programs have been shown to improve diagnosis and treatment r= ates.^8,9 This partnership aims to double the 390 existing Capture the Frac= ture programs by the end of 2022, and will focus on key regions including A= sia Pacific, Latin America, the Middle East, and Europe. =E2=80=9CThe introduction of the post-fracture care model is recognized as = a progressive milestone in the management of osteoporosis and osteoporotic = fractures and remains a profound example of what good looks like in coordin= ation of care among multiple disconnected players,=E2=80=9D said Professor = Dr. Iris Loew-Friedrich, chief medical officer and executive vice president= , UCB. =E2=80=9CCollaboration and cross learning are necessary if we are to= face the challenges of the future and find a way to lessen the burden face= d by healthcare systems and people living with osteoporosis. This global pa= rtnership supports UCB's ambition of connected healthcare, finding ways to = deliver more for the patient and transforming the lives of people with seve= re diseases.=E2=80=9D This partnership also welcomes collaboration from existing fracture prevent= ion coalitions on international, national and regional levels to drive frac= ture prevention policy change and prioritization. Additional elements of th= e partnership include developing and implementing efficiencies and best pra= ctice sharing across PFC program sites, creating a digital tool that docume= nts and communicates PFC effectiveness, and providing virtual and in-person= mentorship and learning opportunities for healthcare providers. =E2=80=9CCapture the Fracture is an incredible opportunity to take the acad= emic skills and expertise from the university to deliver real improvements = in patient care for osteoporosis,=E2=80=9D said Dr. Kassim Javaid, Associat= e Professor, the Nuffield Department of Orthopaedics, Rheumatology and Musc= uloskeletal Sciences (NDORMS), University of Oxford. Dr. Javaid, along with= Dr. Rafael Pinedo-Villanueva, will be responsible for the mentorship progr= am and for developing a benefits calculator for the PFC program. =E2=80=9CW= e hope that through this program millions of lives will be changed, and we = look forward to working with national and international colleagues to deliv= er this vision.=E2=80=9D =C2=A0 For more information about Capture the Fracture, please visit https://u7061= 146.ct.sendgrid.net/ls/click?upn=3DTeZUXWpUv-2B6TCY38pVLo9qUf3L3FF27bxkm-2F= NLvitdTZylHYzWELTHtMUWEg9A89ydnW_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI= 3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrt= M6DlJeULeIaUcHdhgXOVk1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD= 0Q5c5EzzTZzSxRY39vwp0gv33z2ig2soC93Tu-2FJB9S5u6I494cMr-2B1kj5akKu5VW8gODIen= -2BRgH1-2FwOpTJdthudGcW3YMaIWywwLbGn4O2WMfE5GST6Yeqn4xvVZWj5rMa-2F4TtcvOQ0T= sbRNJQpS5irT0PdTHdht9Wbj-2F8RQ3d9SN45OA-3D (https://u7061146.ct.sendgrid.ne= t/ls/click?upn=3DTeZUXWpUv-2B6TCY38pVLo9qUf3L3FF27bxkm-2FNLvitdQHhG5QHvFQJu= 94CFxdFmNiaTfe_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0Kx= vPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgX= OVk1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39v= wp0gv33z2ihNmveUCTBXwvgcX-2FsjREXeAqkrX4B8WXNn1JRUybZcI7v74fdmzbqxm11kKeluY= ytCMhfXlTPihfDsXqXnf61DAsa2Xpwhtkci3D-2FU8jhI-2Fv5GWQ4RMzSVYrx6HFEAHI6JpNAy= lmPTMwdaVNw5ZtI-3D .=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With 7 500 people in approxima= tely 40 countries, the company generated revenue of =E2=82=AC 4.9 billion i= n 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit= ter: @UCB_news (https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8i= DZJQyQ53jATUe2lj6oWHHXtZgwkiNwqDdXnOq5rqXLFB-2FdXpffw9GyGTe7T_xDPID0vOuylFA= U8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2F= OeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk1wLTP3tkYficVDrAo3nBwyaPQ= Bl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp0gv33z2v-2ButxT-2Bq80DJyGU= 8ZGG76Q5zbrO8mGefRnYPWe3axTqXWpXyrha1E-2FUPq-2B8yG0DIjss5s48W1fqPVFoJErCV-2= B1wCmIrShmTe-2BUxDiPZIYMBj-2FI0M4dH26YhP6cEh5z69YHbsKZeielzJMiGxzQse0g-3D About Amgen Amgen is committed to unlocking the potential of biology for patients suffe= ring from serious illnesses by discovering, developing, manufacturing and d= elivering innovative human therapeutics. This approach begins by using tool= s like advanced human genetics to unravel the complexities of disease and u= nderstand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its experti= se to strive for solutions that improve health outcomes and dramatically im= prove people's lives. A biotechnology pioneer since 1980, Amgen has grown t= o be one of the world's leading independent biotechnology companies, has re= ached millions of patients around the world and is developing a pipeline of= medicines with breakaway potential. For more information, visit www.amgen.com (https://u7061146.ct.sendgrid.net= /ls/click?upn=3DTeZUXWpUv-2B6TCY38pVLo9pz6KCxeXhEjlt-2BBs9dbF7o-3D7uxo_xDPI= D0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlG= B52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk1wLTP3tkYficVDrA= o3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp0gv33z2rTTrlpa6mW= SQCrLM8VlVIG02yz9Df6V2qIb2XG9nRoUp4JeHjq5qVti7bQ2WFczk2YtOKJdpZlXW9lAxr68ub= xJ3INODx1h-2FDpBNRdEFZMTJ2tqWsRFvqIq1jFtFXMyzmbQG5z0SmRtuwuYK-2BPwvVI-3D an= d follow us on www.twitter.com/amgen (https://u7061146.ct.sendgrid.net/ls/c= lick?upn=3DTeZUXWpUv-2B6TCY38pVLo9pra2icLBqlEoqemsTLgKvbdUoyoa9gNgsI1xu6-2B= uRexuKer_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EF= aZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk1wL= TP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp0gv3= 3z2rzsFlLoiIykoKIib2S2byywFeSY3X536n6cryQYnSlTx0OKn-2FivOEZ9w8HiiweV5QcuI1v= epsBS7IIgusmTM5a6OW8WnKerrpkFXxt48qA-2BzMwZ4-2BE6-2BX4JAzy2RqRWb78QwKWOsEKs= giWo1vofTS0-3D . About International Osteoporosis Foundation The International Osteoporosis Foundation (IOF) is a registered not-for-pro= fit, non-governmental foundation based in Switzerland. =C2=A0IOF has been g= ranted Roster Consultative Status with the Economic and Social Council of t= he United Nations. IOF functions as a global alliance of patient societies, research organizat= ions, healthcare professionals and international companies working to promo= te bone, muscle and joint health. www.iofbonehealth.org (https://u7061146.c= t.sendgrid.net/ls/click?upn=3DTeZUXWpUv-2B6TCY38pVLo9h4bsj0O2glpZM95aXDR2tj= nATLq2hJ-2F1qxAbFNh6U7hFcvE_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sY= N46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJ= eULeIaUcHdhgXOVk1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5= EzzTZzSxRY39vwp0gv33z2sep4yZ5DZ2Ek1KAJ4EfR0NFTBRVpmiJZpBEXXJ-2BEfuc-2FGTQ2X= m4O320LS8CHtUh5o5Xz0aYoFnSMUfQ-2BWJwu3jjfJwA4ovzfxFHEtFKXwbCKyu-2FTb8rTehy-= 2F5d7csJbksep6is9JqlmTv-2BuP0sQEo8-3D =C2=A0 About University of Oxford Oxford University has been placed number 1 in the Times Higher Education Wo= rld University Rankings for the fourth year running, and at the heart of th= is success is our groundbreaking research and innovation. Oxford is world-famous for research excellence and home to some of the most= talented people from across the globe. Our work helps the lives of million= s, solving real-world problems through a huge network of partnerships and c= ollaborations. The breadth and interdisciplinary nature of our research spa= rks imaginative and inventive insights and solutions. About The Nuffield Department of Orthopaedics, Rheumatology and Musculoskel= etal Sciences (NDORMS) The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal S= ciences (NDORMS) is a multi-disciplinary department focusing on discovering= the causes of musculoskeletal and inflammatory conditions to deliver excel= lent and innovative care that improves people=E2=80=99s quality of life. Th= e largest European academic department in its field, NDORMS is part of the = Medical Sciences Division of the University of Oxford and is a rapidly grow= ing community of more than 500 orthopaedic surgeons, rheumatologists and sc= ientists all working in the field of musculoskeletal disorders.=C2=A0 The research work of the department takes place in several locations across= the Nuffield Orthopaedic Centre, namely the Botnar Research Centre, the Ke= nnedy Institute of Rheumatology, and the Kadoorie Centre. The co-location w= ith NHS services puts the department in an excellent position with basic re= searchers working alongside clinicians. This substantially improves researc= h capacity, improving access for researchers to patients, and facilitating = the interaction between clinicians and scientists that is essential for suc= cessful medical research. www.ndorms.ox.ac.uk=C2=A0 (https://u7061146.ct.se= ndgrid.net/ls/click?upn=3DTeZUXWpUv-2B6TCY38pVLo9nWtZDqTmfr3U95QAuxlGnhVBO-= 2BiL5oWVHAxejxpH-2BdBIIY6_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN4= 6DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeU= LeIaUcHdhgXOVk1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5Ez= zTZzSxRY39vwp0gv33z2pTtDwH0KTvqvYiN8Sr0FjhLZoU7V8IWOZ19KEwWfp612M9jCxkxIfMv= 4xVKfGhBBvIyHOgimsblPPs-2B6ICzadzbwRhgZWR6G73Bh4HqOZnpkpPyqB-2BvFzBZTaRbnZ1= Yy6PmwwRkWNU-2FKkKf4UDpC5A-3D CONTACT: UCB Scott Fleming, Bone Communications, UCB, T +44 7702777378, scott.fleming@uc= b.com CONTACT: Amgen, Thousand Oaks Jessica Akopyan, 805-447-0974 (media)=C2=A0 Trish Rowland, 805-447-5631 (media) CONTACT: International Osteoporosis Foundation=C2=A0 Laura Misteli, Communications Editor, T +41 0788571777, lmisteli@iofbonehea= lth.org=C2=A0 CONTACT: University of Oxford Josie Eade, Communications Officer, josie.eade@ndorms.ox.ac.uk=C2=A0 References 1. International Osteoporosis Foundation. IOF Compendium of Osteoporosis 2n= d Edition. https://u7061146.ct.sendgrid.net/ls/click?upn=3DTeZUXWpUv-2B6TCY= 38pVLo9sJO4tVPGSp90Wl6WPmfSYyjM5cp8ppVqcAEIsVC-2FERWFu0odxcRMghNKSx7sSvP-2B= A4yOj-2F-2FV3zosR-2B-2F5-2FGduSri0Vx8Vp1aqPQWYmbGvj2kRGqHEO665krw-2FV8PfxQ6= jCTe7QLVjRM5Gb0SWo01iqWNBwJoVjMuStnYcG0Cn-2BNOvZkJ_xDPID0vOuylFAU8fv4e60wei= 4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekoc= Vj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGR= Iups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp0gv33z2tNYbLj9mc-2Ba2-2F-2BR97CknChS1= -2BPV-2BN2319G7x-2BXbJsBqtv4SG1Nmhms-2FeGBMcsJ8UKvH8Q6S3M9DQN-2F8oa2VcIVnhd= stJiV6NxvXMHsue-2BH75BPvPX6zcJqxtsq4mLPrABIrU7ooGw6B004U6oTSo9c-3D Accessed= March 11, 2020.=C2=A0 2. Burge R, Dawson-Hughes B, Solomon DH, et alWong JB, King A, Tosteson A. = Incidence and economic burden of osteoporosis-related fractures in the Unit= ed States, 2005-2025. J Bone Miner Res. 2007; Mar;22(3):465-475. 3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disabil= ity associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-17= 33. 4. Reginster JY, Burlet N. Osteoporosis: A still increasing prevalence. Bon= e. 2006;38 (2 Suppl 1):S4-S9 5. International Osteoporosis Foundation. Capture The Fracture =E2=80=93 A = global campaign to break the fragility fracture cycle (October 2012). https= ://u7061146.ct.sendgrid.net/ls/click?upn=3DLHDupLGQbJrIBf0glmWFG9c6aAw-2FQ2= erDzz9hLlBcpgmE5yazRTn3TgK8yKVUoTNGepAxmmyMOt84Jr76fHP5f4Hm59Y5J0g-2BhvPa7a= lGRw-3D_HrV_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs= 6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk= 1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp0= gv33z2tXUXXnm9Ilmn5YC-2BnOXw6m-2FVC4CP0G8F9-2FCyUgsUG6ogSxcpm-2FATQYIwV1S-2= FYm-2FLCDNi8IiD2LxWZ8XF1gPGuc6wEg6AUTcL-2F-2F37Zg2wi5uMv-2BDI3whT-2B5HKmu7X= h2SlUay-2BQ0exOH-2FJ-2BT02FDsNx4-3D Accessed March 11, 2020. 6. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnose= d and undertreated. Med J Aust. 2004;180:S18-S22. 7. Kanis JA, De LAet C, Delmas P, Garnero P, Johansson H, Johnell O, Kriger= H, McCloskey EV, Mellstrom D, Melton LJ III, Od=C3=A9n A, Pols H, Reeve J,= Silman A, Tenenhouse A. A meta-analysis of previous fracture and fracture = risk. Bone 2004 35;375-82 8. Akesson et al. Capture the Fracture: a Best Practice Framework and globa= l campaign to break the fragility fracture cycle. Osteoporos Int. 2013 Aug;= 24(8):2135-52 9. Ganda et al. Models of care for the secondary prevention of osteoporotic= fractures: a systematic review and meta-analysis Osteoporos Int (2013) 24:= 393=E2=80=93406 GenericFile UCB CTF Partnership Release June 16 2020 ENG (https://u7061146.ct.sendgrid.= net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6empSJP3S5= WNEmfu8d-2FxLPeXIY1kjJMuRbh8ssZ1jcigyb-2BIAcuTqG3gXSQthJMGWhs-3D6RZP_xDPID0= vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB5= 2Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOVk1wLTP3tkYficVDrAo3= nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp0gv33z2jkx7GKZICJRy= ZTsuvJAK-2BoUHCDLYhVBkppJY77phTzsYsfwnkfeLiZxKVqoMATZyd6QnN7h7m-2F2eSg-2Bmb= 0GYNP9weQcdtxlhJURFo-2Be0IVb5gbDk91ufX4LU-2FPmzhIvUC0No-2BshMCmgf7WMXmwxbMI= -3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT= UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXyjraN4KhOJcry7wrvsfweZWvkAwnZRZ= NSK7VzSE1tAOvqzuxWOZ557DAnvOoblfFjBkEoplHQmGgYITf36t-2BC2sKpCrRW7-2FhxEPT5n= Ln0NU-3DpDoI_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvP= s6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wYOvrtM6DlJeULeIaUcHdhgXOV= k1wLTP3tkYficVDrAo3nBwyaPQBl6HP1DLNGRIups9LLua4VsoarxeD0Q5c5EzzTZzSxRY39vwp= 0gv33z2ktUfwwzCZ9fPEjiSmK2RCLRcURw7YbX7-2Bfqfjv7AQWZtNZTg0DFnogGbqCpcdaGCHb= ktlOf-2FxsZBYo05RckmkFuyNT39B7-2BT6RHn3kN2jAOeAGe7oynUj4mRiZMl0YClM4sqWVISc= 3jRIxZ-2FYY7jg0-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

UCB's latest news

25/04/2024 07:01

UCB (EBR:UCB) UCB Media Room: Capture the Fracture Partnership

Transparency directive : regulatory news

UCB's latest news

Other stories